Is Maravai Lifesciences Holdings Inc (MRVI) overvalued? · rev $117.3M
Maravai Lifesciences Holdings Inc (MRVI) is a biotechnology company listed on NASDAQ.
This page asks whether Maravai Lifesciences Holdings Inc (MRVI) looks expensive on cached numbers — not a short thesis.
Latest reported MRVI revenue for 2026-06-30 was $117.3M. Net income was -$16.1M. Revenue was up 78.1% from 2026-03-31 to 2026-06-30. MRVI currently screens at market cap $1.93B.
MRVI currently screens at market cap $1.93B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next MRVI 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the MRVI stock page for the full model, not this heading.
Not investment advice.